Onconova Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to the OncoNova Therapeutics First Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at this time, please press star followed by one on your touchtone phone. If anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this call is being recorded today, May 15th, 2023. At this time, I would like to turn the call over to Bruce Mackle of Lifestyle Advisors. Please go ahead, Bruce.

Thank you, operator, and welcome everyone to Ankenova's first quarter 2023 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release reporting its financial results and business progress. If you have not yet seen this press release, it is available in the Investors in Media section of the company's website at Onconova.com. Following my introduction, we will hear from Onconova's President and CEO, Dr. Steve Fruchman, Interim Chief Medical Officer, Dr. Michael Saunders, and Chief Operating Officer and Chief Financial Officer, Mark Guerin. Onkonova's VP of Regulatory Affairs and Quality Assurance, Fred Frullo, will also be available during a Q&A session following the prepared remarks. Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. For more information on forward-looking statements, please review the disclaimer in today's press release and the risk factors in the company's SEC filings. With that, I will now turn the call over to Onconova's President and CEO, Dr. Steve Fruchman.

Thanks, Bruce, and thanks to all for listening.